Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction

Olivieri, Fabiola; Antonicelli, Roberto; Lorenzi, Maria; D’Alessandra, Yuri; Lazzarini, Raffaella; Santini, Gabriele; Spazzafumo, Liana; Lisa, Rosamaria; Sala, Lucia La; Galeazzi, Roberta; Recchioni, Rina; Testa, Roberto; Pompilio, Giulio; Capogrossi, Maurizio C.; Procopio, Antonio Domenico

doi:10.1016/j.ijcard.2012.01.075

Cited by 215 publications

(208 citation statements)

References 44 publications

Supporting

Mentioning

187

Contrasting

Unclassified

Order By: Relevance

“…In this respect, miRNAs might help to improve the diagnostic accuracy of blood-based biomarkers in AMI. For example, miR-499-5p was identified as highly increased in patients with non-ST segment elevation MI (NSTEMI) [23]. Analogous to the above results concerning miR-208, the power of miR-499-5p to discriminate NSTEMI from healthy controls was similar to cTnT [23].…”

Section: Diagnostic Biomarkers Single Mirnas In the Diagnosis Of Acutmentioning

confidence: 53%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

100

View full text Add to dashboard Cite

microRNAs (miRNAs) are well-known, powerful regulators of gene expression, and their potential to serve as circulating biomarkers is widely accepted. In cardiovascular disease (CVD), numerous studies have suggested miRNAs as strong circulating biomarkers with high diagnostic as well as prognostic power. In coronary artery disease (CAD) and heart failure (HF), miRNAs have been suggested as reliable biomarkers matching up to established protein-based such as cardiac troponins (cT) or natriuretic peptides. Also, in other CVD entities, miRNAs were identified as surprisingly specific biomarkers -with great potential for clinical applicability, especially in those entities that lack specific protein-based biomarkers such as atrial fibrillation (AF) and acute pulmonary embolism (APE). In this regard, miRNA signatures, comprising a set of miRNAs, yield high sensitivity and specificity. Attempts to utilize miRNAs as therapeutic agents have led to promising results. In this article, we review the clinical applicability of circulating miRNAs in CVD. We are giving an overview of miRNAs as biomarkers in numerous CVD entities to depict the variety of their potential clinical deployment. We illustrate the function of miRNAs by means of single miRNA examples in CVD.

show abstract

Section: Diagnostic Biomarkers Single Mirnas In the Diagnosis Of Acutmentioning

confidence: 53%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

100

View full text Add to dashboard Cite

show abstract

“…miR-499-5p and miR-21 showed increased expression in NSTEMI compared to 81 patients with CHF. mir-499-5p also showed good diagnostic accuracy in differentiating patients with NSTEMI and CHF [78] . Takotsubo cardio- [79] .…”

Section: Plasma Mirnas For Differentiating MI From Other Cardiovasculmentioning

confidence: 82%

miRNome in myocardial infarction: Future directions and perspective

Boštjančič

Glavač

2014

WJC

View full text Add to dashboard Cite

MicroRNAs (miRNAs), which are small and non-coding RNAs, are genome encoded from viruses to humans. They contribute to various developmental, physiological and pathological processes in living organisms. A huge amount of research results revealed that miRNAs regulate these processes also in the heart. miRNAs may have cell-type-specific or tissue-specific expression patterns or may be expressed ubiquitously. Primary studies of miRNA involvement in hypertrophy, heart failure and myocardial infarction analyzed miRNAs that are enriched in or specific for cardiomyocytes; however, growing evidence suggest that other miRNAs, not cardiac or muscle-specific, play a significant role in cardiovascular disease. Abnormal miRNA regulation has been shown to be involved in cardiac diseases, suggesting that miRNAs might affect cardiac structure and function. In this review, we focus on miRNAs that have been found to contribute to the pathogenesis of myocardial infarction (MI) and the response post-MI and characterized as diagnostic, prognostic and therapeutic targets. The majority of these studies were performed using mouse and rat models of MI, with a focus on the identification of basic cellular and molecular pathways involved in MI and in the response post-MI. Much research has also been performed on animal and human plasma samples from MI individuals to identify miRNAs that are possible prognostic and/or diagnostic targets of MI and other MI-related diseases. A large proportion of research is focused on miRNAs as promising therapeutic targets and biomarkers of drug responses and/or stem cell treatment approaches. However, only a few studies have described miRNA expression in human heart tissue following MI.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: MicroRNAs; Myocardial infarction; Human; Animal models; Biomarkers and targets Core tip: MicroRNAs (miRNAs) contribute to various developmental, physiological and pathological processes in the heart. Cardiac diseases show abnormal miRNA regulation. Primary studies of miRNA involvement in cardiac disease analyzed mainly miRNAs that enriched in or specific for cardiomyocytes; however, growing evidence suggests that other cell-type-specific or ubiquitously expressed miRNAs are also involved in cardiovascular disease. miRNAs were found to contribute to the pathogenesis of myocardial infarction (MI) and post-MI. The majority of studies focused on miRNAs in animal models of MI, in human and animal plasma samples of MI (prognostic and diagnostic targets), and on miRNAs as promising therapeutic targets.Boštjančič E, Glavač D. miRNome in myocardial infarction: Future directions and perspective. World J Cardiol 2014; 6(9): 939-958 Available from:

show abstract

“…Circulating miRNA-499-5p, a family member of miRNA-499, was shown to have the highest increase in NSTEMI patients by ~80-fold, and exhibited the greatest discrimination between NSTEMI and CHF patients groups, in the total population, the expression levels of miRNA-499-5p was significantly correlated with cTnT, the diagnostic accuracy of miRNA-499-5p was evaluated with ROC analyses, and was comparable to that of cTnT (22). In the elderly patients with acute NSTEMI, a study showed that circulating miRNA-499-5p had better accuracy in the diagnosis compared with cTnT (23).…”

Section: Plasma Level Of Mirna-499 and Ami Diagnosismentioning

confidence: 99%

Circulating miR-499 as a potential biomarker for acute myocardial infarction

Xin¹,

Yang²,

Han³

2016

Ann. Transl. Med.

View full text Add to dashboard Cite

Acute myocardial infarction (AMI), a common heart disease that may lead to chronic heart failure, is the leading cause of morbidity and mortality worldwide. MicroRNAs (miRNAs) are small non-coding RNAs that mediate the expression of target genes. Recently, a number of miRNAs are emerging as potential biomarkers of AMI. MiRNA-499 is a newly discovered member of miRNAs, and is mainly expressed in myocardium, the circulating levels of miRNA-499 was increased in AMI patients. This review summarizes the latest advances in the miRNA-499 study and discusses the potential of miRNA-499 to be a biomarker of AMI. Acute myocardial infarction (AMI) is one of the leading causes of morbidity and mortality worldwide, thus an effective and accurate diagnostic biomarker would be needed to help decrease the mortality of AMI patients. One of the traditional biomarkers for AMI is troponin. Circulating troponin levels rise around 3 hours after the onset of chest pain, due to the relative delayed release time of troponin. It is widely believed that a rapid and correct diagnosis of AMI has an important impact on patients' treatment and prognosis. Therefore, earlier biomarkers than troponin with both high sensitivity and specificity remain to be needed. MicroRNAs (miRNAs) are endogenous small non-coding RNAs of less than 22 nucleotides that are implicated in nearly all cellular events including cell differentiation and proliferation as well as the pathogenesis of certain human diseases (1,2). Recently, a number of findings support the notion of the implication of miRNAs in the development and progression of cardiovascular diseases (3). The plasma levels of miRNA-1, -133a, -133b, and -499-5p are upregulated in AMI patient, and represent novel biomarkers of cardiac damage. Several reviews have provided an over-view of biology of miRNA-1, miRNA-133b, -499-5p and their involvement in cardiovascular physiology and pathology, and discussed the potential of these miRNAs to become a novel biomarker of AMI and even an effective therapeutics agent (4-8). miRNA-499 is a newly discovered member of miRNAs encoded by myosin gene family, and its expression level in plasma was elevated in the patients with AMI, a common heart disease that is the leading cause of morbidity and mortality worldwide (9). A previous study compared the diagnostic performance of miRNA-499 and some traditional biomarkers like SMB, cTnI, cTnT, CK-MB, CK, LDH, and concluded that miRNA-499 was present in plasma earlier than other conventional biomarkers of AMI, pointing to the likelihood that miR-499 can be a vital molecule in the early diagnosis of AMI. This study also found that the circulating level of miR-499 correlated well with circulating troponin I

show abstract

Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction

Cited by 215 publications

References 44 publications

microRNAs in cardiovascular disease – clinical application

microRNAs in cardiovascular disease – clinical application

miRNome in myocardial infarction: Future directions and perspective

Circulating miR-499 as a potential biomarker for acute myocardial infarction

Contact Info

Product

Resources

About